---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-086275"
form_type: "8-K"
ticker: "ICCC"
cik: "0000811641"
company_name: "IMMUCELL CORP /DE/"
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:49:35.390024+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# ImmuCell reports Q3 2024 preliminary sales of $6.0M, up 11% YoY; backlog $7.3M

## Summary
- Q3 2024 total sales $6.0M (+11% YoY); nine-month sales $18.7M (+51% YoY).
- Twelve-month sales $23.8M (+46% YoY); production at 77% of ~$30M annual capacity.
- Backlog of orders $7.3M; reflects strong demand as distributors replenish stocks.
- Plans to submit Re-Tain NADA later this year after contract manufacturer resolves FDA issues.
- Conference call on Nov 14, 2024 at 9:00 AM ET to discuss full Q3 results.

## SEC filing metadata
- accession: 0001213900-24-086275
- form_type: 8-K
- ticker: ICCC
- cik: 0000811641
- company_name: IMMUCELL CORP /DE/
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/811641/000121390024086275/0001213900-24-086275-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/811641/000121390024086275/ea0217094-8k_immu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-086275
- JSON: https://secwatch.observer/filing/0001213900-24-086275.json
- Plain text: https://secwatch.observer/filing/0001213900-24-086275.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.